A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.

Authors :: Ramo-Tello, C
Grau-López, L
Tintoré, M
Rovira, A
Ramió i Torrenta, L
Brieva, L
Cano, A
Carmona, O
Saiz, A
Torres, F
Giner, P
Nos, C
Massuet, A
Montalbán, X
Martínez-Cáceres, E
Costa, J
Source :: Multiple Sclerosis Journal; May2014, Vol. 20 Issue 6, p717-725, 9p, 1 Diagram, 5 Charts, 1 Graph
Publication Year :: 2014
Abstract: The article focuses on the study which compares the clinical and radiologic efficacy of intravenous methylprednisolone (ivMP) against oral methylprednisolone (oMP) at equivalent high doses for multiple sclerosis (MS) relapse. It states the main outcome of noninferiority at four weeks for improved expanded disability status scale (EDSS) score. It mentions that oMP is not inferior to ivMP in reducing the score of EDSS.

Subjects :: METHYLPREDNISOLONE
ORAL drug administration
DISEASE relapse
MULTIPLE sclerosis
DOSAGE forms of drugs
THERAPEUTICS

Full Text Access

Tools